Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$49.09 USD

49.09
3,285,409

-0.04 (-0.08%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $49.00 -0.09 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

by Kinjel Shah

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

by Zacks Equity Research

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

by Zacks Equity Research

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

by Zacks Equity Research

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

The Zacks Analyst Blog Highlights Oracle, Abbott Laboratories, Sanofi, Realty Income and Hilton Worldwide Holdings

by Zacks Equity Research

Oracle, Abbott Laboratories, Sanofi, Realty Income and Hilton Worldwide Holdings are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Oracle, Abbott & Sanofi

by Sheraz Mian

Today's Research Daily features new research reports on 15 major stocks, including Oracle Corporation (ORCL), Abbott Laboratories (ABT) and Sanofi (SNY).

Why Sanofi (SNY) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?

by Zacks Equity Research

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Sanofi (SNY) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU

by Zacks Equity Research

Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.

Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women

by Zacks Equity Research

The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

by Zacks Equity Research

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.

Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies

by Zacks Equity Research

Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.

Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues

by Zacks Equity Research

Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III

by Kinjel Shah

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.

Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody

by Kinjel Shah

FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.

Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants

by Zacks Equity Research

Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.

Microsoft (MSFT) Agrees to Keep Call of Duty on Sony PlayStation

by Zacks Equity Research

Microsoft (MSFT) and Sony sign a deal to keep Call of Duty video game series on PlayStation consoles as its planned acquisition of Activision Blizzard appears closer to completion.

This is Why Sanofi (SNY) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.